At Wilmington Pharmaceuticals, we develop and out-license patient-friendly, fast-dissolving formulations for established medicines. We achieve FDA approval and rapid commercialization for our licensing partners, minimizing regulatory risk while maximizing economic opportunity. Our points of differentiation provide you with an ideal development partner.
Reference: 1. Schwartz JI, Yeh KC, Berger ML, et al. Novel oral medication delivery system for famotidine. J Clin Pharmacol. 1995;35:362-367.
Zydis® is a registered trademark of Catalent Pharma Solutions.
75% of patients expressed a preference for
the fast-dissolve formulation compared with a tablet.1
Click here to learn more.
“Numerous surveys have shown that a majority of patients would prefer to receive their medicine in a fast-dissolve format. Addressing this significant unmet patient need can translate into meaningful market shares and high returns on investment.”